NutriBand (NTRB) Cash from Financing Activities (2016 - 2026)
NutriBand (NTRB) posted Cash from Financing Activities of -$5569.0 for Q2 2026, down 1.44% sequentially from -$5490.0 in Q1 2026, and down 4.6% YoY from -$5837.6 in Q2 2025.
NutriBand (NTRB) Cash from Financing Activities (2016 - 2026) Analysis & Trends
NutriBand has reported Cash from Financing Activities for 11 years, with the latest figure at -$5569.0 in Q2 2026.
- Quarterly Cash from Financing Activities fell 4.6% year-over-year to -$5569.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $5.4 million (up 3417.5% YoY) and the FY2026 annual result came in at $5.4 million, down 36.71% from the prior year.
- Cash from Financing Activities retreated to -$5569.0 in Q2 2026 per NTRB's latest filing, from -$5490.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $8.7 million in Q2 2024 and troughed at -$147224.0 in Q1 2025.
- A 5-year average of $936162.1 and a median of -$5070.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 104156.52% in 2025, down 2842.13% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$6525.0 in 2022, then climbed by 23.98% to -$4960.0 in 2023, then slipped by 4.33% to -$5175.0 in 2024, then soared by 1444.21% to $69563.0 in 2025, then tumbled by 108.01% to -$5569.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5569.0, -$5490.0, and $69563.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | -5,569.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -5,569.00 |
| Apr 30, 2026 | -5,569.00 |
| Jan 31, 2026 | -5,490.00 |
| Jan 31, 2026 | -5,490.00 |
| Oct 31, 2025 | 69,563.00 |
| Oct 31, 2025 | 69,563.00 |
| Jul 31, 2025 | 5.34 Mn |
| Jul 31, 2025 | 5.34 Mn |
| Apr 30, 2025 | -5,324.00 |
| Apr 30, 2025 | -5,324.00 |
| Jan 31, 2025 | -147,224.00 |
| Jan 31, 2025 | -147,224.00 |
| Oct 31, 2024 | -5,175.00 |
| Oct 31, 2024 | -5,175.00 |
| Jul 31, 2024 | -5,136.00 |
| Jul 31, 2024 | -5,136.00 |
| Apr 30, 2024 | 8.69 Mn |
| Apr 30, 2024 | 8.69 Mn |
| Jan 31, 2024 | -5,004.00 |
| Jan 31, 2024 | -5,004.00 |